LivaNova (LIVN) Publishes 36-Month CORE-VNS Study Results on Drug-Resistant Epilepsy

gurufocus.com · 2026-10-23

On October 23, 2026, LivaNova PLC (NASDAQ: LIVN) announced the publication of comprehensive 36-month follow-up results from the CORE-VNS study in the journal Ne

TickrTrends take: LivaNova's publication of extended clinical data on its vagus nerve stimulation therapy represents the type of long-term evidence that can support market confidence in its core product portfolio within the medical device space. Given TickrTrends' assessment that LIVN is fairly valued, investors should monitor whether this positive efficacy data translates into expanded market adoption or pricing power that could justify a higher valuation multiple. The durability of treatment benefits demonstrated in a multi-year study addresses a key question for investors evaluating whether the company's current valuation appropriately reflects the competitive strength of its neuromodulation franchise.

Read the full story at gurufocus.com →